Compare Nerdwallet Inc (NRDS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs Sanofi SA — how do they compare? Nerdwallet Inc trades at $9.41 (market cap $610.79M), while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Sanofi SA is far larger — about 170.4× Nerdwallet Inc's market cap, and Sanofi SA pays a 5.61% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| NRDS | SNY | |
|---|---|---|
Market Cap | $610.79M | $104.06B |
Sector | Financials | Health |
52-Week High | $15.93 | $52.34 |
52-Week Low | $7.58 | $41.33 |
Enterprise Value | $525.09M | $124.09B |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRDS trades at $9.56, down 3.24% amid bearish technical signals, though fundamentals show strong improvement with revenue growing from $539M in 2022 to $837M in 2025 and net income turning positive. The stock appears undervalued with a P/E of 10.62 and P/S of 0.79, while analyst sentiment remains positive with 4 out of 6 ratings being Buy. Recent Q2 2026 earnings missed expectations but management highlights an inflection point in business operations.
The outlook is mixed: strong profitability metrics (93.5% gross margin, 18.16% ROE) and analyst price targets suggesting 27.9% upside support bullish case, but technical weakness and competitive pressures in credit card/search segments pose near-term risks. Execution on Q3 guidance and sustained cash flow generation will be critical for stock performance.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
